Compare General Dynamics Corporation (GD) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Dynamics Corporation vs IDEXX Laboratories, Inc. — how do they compare? General Dynamics Corporation trades at $331.27 (market cap $89.26B), while IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B). The key difference: General Dynamics Corporation is far larger — about 2.2× IDEXX Laboratories, Inc.'s market cap, and General Dynamics Corporation pays a 1.93% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Dynamics Corporation for 85 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| GD | IDXX | |
|---|---|---|
Market Cap | $89.26B | $40.43B |
Volume | 1,496,273 | 692,164 |
Sector | Industrials | Health |
52-Week High | $395.97 | $766.68 |
52-Week Low | $312.53 | $504.70 |
Typical Hold Time | 85 Days | 46 Days |
Enterprise Value | $94.40B | $41.32B |
Dividend Yield | 1.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Dynamics (GD) trades at $329.90, up 1.0% with strong fundamental performance including three consecutive quarterly earnings beats and robust 2025 revenue of $52.55 billion. The stock shows bearish technical signals despite positive analyst sentiment with a $420.57 consensus price target representing 27.5% upside potential. Defense sector tailwinds from Pentagon spending and dividend stability support the investment case.
GD presents a compelling value opportunity with reasonable valuation multiples (P/E 20.12, P/S 1.65) and strong profitability metrics (ROE 17.8%, net margin 8.18%). Key risks include defense budget volatility and technical weakness, but the company's consistent earnings performance and analyst support suggest potential for medium-term appreciation.
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
